A detailed history of Citigroup Inc transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 151,493 shares of MIRM stock, worth $6.78 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
151,493
Previous 212,504 28.71%
Holding current value
$6.78 Million
Previous $7.27 Million 18.68%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$33.68 - $44.74 $2.05 Million - $2.73 Million
-61,011 Reduced 28.71%
151,493 $5.91 Million
Q2 2024

Aug 12, 2024

SELL
$23.57 - $34.85 $3.74 Million - $5.53 Million
-158,547 Reduced 42.73%
212,504 $7.27 Million
Q1 2024

May 10, 2024

BUY
$24.92 - $30.02 $7.12 Million - $8.58 Million
285,820 Added 335.35%
371,051 $9.32 Million
Q4 2023

Feb 09, 2024

BUY
$27.14 - $34.93 $719,427 - $925,924
26,508 Added 45.14%
85,231 $2.52 Million
Q3 2023

Nov 09, 2023

BUY
$24.63 - $32.85 $441,295 - $588,573
17,917 Added 43.91%
58,723 $1.86 Million
Q2 2023

Aug 10, 2023

SELL
$23.51 - $30.09 $671,704 - $859,701
-28,571 Reduced 41.18%
40,806 $1.06 Million
Q1 2023

May 11, 2023

SELL
$19.19 - $24.1 $1.88 Million - $2.37 Million
-98,196 Reduced 58.6%
69,377 $1.67 Million
Q4 2022

Feb 09, 2023

BUY
$17.59 - $23.83 $517,269 - $700,768
29,407 Added 21.28%
167,573 $3.27 Million
Q3 2022

Nov 10, 2022

BUY
$19.98 - $29.44 $2.73 Million - $4.02 Million
136,395 Added 7701.58%
138,166 $2.9 Million
Q2 2022

Aug 10, 2022

BUY
$18.42 - $27.5 $17,793 - $26,565
966 Added 120.0%
1,771 $34,000
Q1 2022

May 12, 2022

SELL
$15.5 - $23.93 $16,104 - $24,863
-1,039 Reduced 56.34%
805 $18,000
Q4 2021

Feb 10, 2022

BUY
$13.05 - $19.35 $18,700 - $27,728
1,433 Added 348.66%
1,844 $29,000
Q3 2021

Nov 10, 2021

BUY
$13.95 - $20.18 $5,733 - $8,293
411 New
411 $8,000

Others Institutions Holding MIRM

About Mirum Pharmaceuticals, Inc.


  • Ticker MIRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,751,700
  • Market Cap $1.64B
  • Description
  • Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...
More about MIRM
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.